多胺多羧酸双吡哆醇酯顺磁性金属螯合物及其弛豫性能研究

由二乙三胺五乙酸(DTPA)双酸酐和乙二胺四乙酸(EDTA)双酸酐与维生素B₆族化合物吡哆醇(PN)或其衍生物合成了一系列新型的多胺多羧酸双吡哆醇酯衍生物及其钆(Ⅲ)、锰(Ⅱ)、铁(Ⅲ)等顺磁性金属螯合物,研究了其中钆(Ⅲ)和锰(Ⅱ)螯合物在体外水溶液中对水质子的纵向弛豫性能(R₁).结果表明,所有配体和配合物均有很好的水溶性,且对光和空气稳定.螯合物的弛豫率(T₁)可与其母体螯合物相媲美,如钆-二乙三胺五乙酸二吡哆醇酯(GdDTPA-BPN)和锰-乙二胺四乙酸二吡哆醇酯(MnEDTA-BPN)的弛豫率R₁分别为5.5和3.1L·mmol^-1·s^-1,与其母体螯合物GdDTPA^2-和MnEDTA^2-的R₁值(5.2和2.8L·mmol^-1·s^-1)相当.     

二乙三胺五乙酸二氢吡啶衍生物的合成及Gd(Ⅲ),Fe(Ⅲ),Mn(Ⅱ)配合物的弛豫性能研究

用二乙三胺五乙酸(DTPA)酸酐与二氢吡啶类化合物反应,合成了4种新型的含二氢吡啶基的二乙三胺五乙酸非离子型配体,并进一步合成了其Gd(Ⅲ),Fe(Ⅲ),Mn(Ⅱ)的顺磁性金属配合物.配体和配合物的结构用IR,¹HNMR及元素分析表征.研究了配合物的体外弛豫性能,结果表明,Fe(Ⅲ)和Mn(Ⅱ)配合物弛豫效率R₁ 低于Gd(Ⅲ)配合物的R₁ ,Gd(Ⅲ)配合物的弛豫效率较高,具有作为MRI造影剂的条件.     

肝靶向性磁共振成像造影剂──含D-半乳糖基的DTPA双酰胺钆配合物的研究

通过二乙三胺五乙酸的双N-羟基琥珀酰亚胺活性酯与含氨基的乳糖或D-半乳糖衍生物反应,合成了8种含有D-半乳糖基的二乙三胺五乙酸非离子型配体,并进一步合成了其钆(Ⅲ)配合物. 配体及配合物的结构经IR、¹HNMR与元素分析表征,对配合物的体外弛豫性能和小鼠急性毒性作了初步研究. 家兔的磁共振成像实验表明这类造影剂具有肝靶向的特性.     

肝靶向性磁共振成像造影剂——含D—半乳糖基的DTPA双酰胺钆…

通过二乙三胺五乙酸的双Ｎ－羟基琥珀酰亚胺活性酯与含氨基的乳糖或Ｄ－半乳糖衍生物反应，合成了８种含有Ｄ－半乳糖基的二乙三胺五乙酸非离子型配体，并进一步合成了其钆（Ⅲ）配合物，配体及配合物的结构经ＩＲ，＾１ＨＮＭＲ与元素分析表征，对配合物的体外驰豫性能和小鼠急性毒性作了初步研究，家兔在磁共振成像实验表明这种上类造影剂具有肝靶向的特性。     

含磺胺嘧啶基团的葡聚糖钆配合物的研究

将具有肿瘤靶向性的磺胺嘧啶(SD)、二乙三胺五乙酸(DTPA)与葡聚糖(dextran)大分子侧链羟基偶联,合成葡聚糖大分子配体(SD-Dextran-DTPA),再与金属钆离子Gd3+配合,从而制备肿瘤靶向性葡聚糖大分子钆配合物(SD-Dextran-DTPA-Gd).对所合成的配体及钆配合物进行FTIR、UV和1H-NMR等结构表征,测试了配体及钆配合物在水溶液中的粒径分布和zeta电位、钆配合物的体外弛豫率、细胞摄取与T1加权磁共振成像性能.与小分子钆-二乙三胺五乙酸(Gd-DTPA)相比,SD-Dextran-DTPA-Gd具有较高的弛豫率,对肺癌细胞系H460、乳腺癌细胞系MDA-MB-231和T40D均有较好的亲和性,可被肿瘤细胞较好地摄取,并能获得较好的肿瘤细胞磁共振成像.     

两亲性双核钆(Ⅲ)配合物的合成与肝选择MRI增强

通过二乙三胺五乙酸单环酸酐和乙二胺四乙酸单环酸酐分别与L-赖氨酸苄酯的双酰化反应,制得两种含有双胺羧螯合单元的配体.它们与GdCl₃·6H₂O反应得到相应的两亲性双核钆(Ⅲ)配合物.表征了配体和配合物的结构,测试了配合物的纵向弛豫效能(R1).进行了双DTPA酰(L-赖氨酸苄酯)钆(Gd₂-3_a)的急性毒性和与Gd-DTPA的动物T₁加权成像对比实验.结果表明,这两种新配合物的R1都高于Gd-DTPA.Gd₂-3_a无明显急性毒性,且比Gd-DTPA对肝区实质细胞有更长时间和更大程度的选择性增强.     

多胺多羧酸双吡哆醇酯磁性金属螯合物及其弛豫性能研究

由二乙三胺五乙胺（ＤＴＰＡ）双酸酐和乙二胺四乙酸（ＥＤＴＡ）双酸酐与维生素Ｂ６族化全物吡哆醇（ＰＮ）或其衍生物合成了一系列新型的多胺多羧酸双吡哆醇酯衍生物及其钆、锰、铁等顺磁性金属螯合物，研究了其中钆和锰螯合物在体外水溶液中对水质子的给向弛豫性能，结果表明，所有配体和配合物均有很好的水溶性，且对光和空气稳定，螯合物的驰豫率（Ｔ１）与可与其母体螯全物相媲美，如钆－二乙三胺五乙酸二吡哆醇酯（ＧｄＤＴＰ     

三乙四胺六乙酸钆单核配合物的合成及晶体结构

在水溶液中合成了三乙四胺六乙酸(H₆ttha)钆单核配合物(NH₄)₂[Gd(Httha)]·6H₂O,获得了单晶,并测定了其结构.晶体属单斜晶系,P2₁/c空间群.晶胞参数a=1.0400(4)nm,b=1.2761(4)nm,c=2.3132(4)nm,β=90.89(3)°,V=3.070(2)nm³,Z=4,D_c=1.709g/cm³.R₁=0.0394,F(000)=1612.配合物是单核分子,每个钆离子与来自同一个三乙四胺六乙酸的4个氮原子和5个羧基氧原子配位,配位数为9,形成单帽四方反棱柱型配位多面体.     

大分子聚酯配体及其钆（Ⅲ）配合物的合成和核磁弛豫性能研究

通过二乙三胺五乙酸二酐（ＤＴＰＡＡ）分别与Ｎ－正丁基、正辛基、苄基、对甲苯磺酰基、苯基和对溴苯基取代二乙醇胺共聚，制得一系列大分子配体及其钆（ＩＩＩ）配合物．对所合成的配体和钆配合物进行了表征，并测试了部分钆配合物的核磁弛豫性能．     

肝靶向性聚天冬酰胺磁共振成像造影剂

用吡哆胺(PM)作为肝靶向基团,先与DTPA双N-羟基琥珀酰亚胺活性酯(SuO-DTPA-OSu)反应生成含一个吡哆胺的DTPA单N-羟基琥珀酰亚胺活性酯(SuO-DTPA-PM),再分别与α,β-聚(2-羟乙基)-L-天冬酰胺和α,β-聚(2-胺乙基)-L-天冬酰胺反应,合成了2类肝靶向性大分子配体,并制备了它们的Gd(Ⅲ)配合物.对所合成的大分子配体以及钆配合物进行了表征.测试了配合物的弛豫率.初步测试大分子载体PHEA和PAEA及其钆配合物的细胞毒性.研究了大分子配体在小白鼠体内分布和大分子钆配合物对大白鼠肝脏造影成像性能.结果表明,与临床广泛应用的小分子磁共振成像造影剂Gd-DTPA相比,以上2类大分子造影剂的弛豫率有明显的提高,并且具有较好的肝靶向性和肝脏成像对比度及清晰度.     

Studies on Hepatocyte-Targeting Magnetic Resonance Imaging Macromolecular Contrast Media

ＳｔｕｄｉｅｓｏｎＨｅｐａｔｏｃｙｔｅ┐ＴａｒｇｅｔｉｎｇＭａｇｎｅｔｉｃＲｅｓｏｎａｎｃｅＩｍａｇｉｎｇＭａｃｒｏｍｏｌｅｃｕｌａｒＣｏｎｔｒａｓｔＭｅｄｉａ＊ＦＵＹａｎ－ｊｕｎａｎｄＺＨＵＯＲｅｎ－ｘｉ＊＊（ＤｅｐａｒｔｍｅｎｔｏｆＣｈｅｍｉｓｔ...     

A series of three-dimensional lanthanide coordination polymers with rutile and unprecedented rutile-related topologies

The complexes of formulas Ln(pydc)(Hpydc) (Ln = Sm (1), Eu (2), Gd (3); H2pydc = pyridine-2,5-dicarboxylic acid) and Ln(pydc)(bc)(H2O) (Ln = Sm (4), Gd (5); Hbc = benzenecarboxylic acid) have been synthesized under hydrothermal conditions and characterized by elemental analysis, IR, TG analysis, and single-crystal X-ray diffraction. Compounds 1-3 are isomorphous and crystallize in the orthorhombic system, space group Pbcn. Their final three-dimensional racemic frameworks can be considered as being constructed by helix-linked scalelike sheets. Compounds 4 and 5 are isostructural and crystallize in the monoclinic system, space group P2(1)/c. pydc ligands bridge dinuclear lanthanide centers to form the three-dimensional frameworks featuring hexagonal channels along the a-axis that are occupied by one-end-coordinated bc ligands. From the topological point of view, the five three-dimensional nets are binodal with six- and three-connected nodes, the former of which exhibit a rutile-related (4.6(2))(2)(4(2).6(9).8(4)) topology that is unprecedented within coordination frames, and the latter two species display a distorted rutile (4.6(2))(2)(4(2).6(10).8(3)) topology. Furthermore, the luminescent properties of 2 were studied.     

Synthesis of Two Derivatives of 3,6,9‐tri(carboxymethyl)‐3,6,9‐triazaundecanedioic Acid and the Stabilities of Their Complexes with Ca2+, Cu2+, Zn2+, Dy3+ and Gd3+

Two N‐2‐hydroxy‐1‐phenylethyl and N‐2‐hydroxy‐2‐phenylethyl derivatives of DTPA (3,6,9‐tri(carboxymethyl)‐3,6,9‐triazaundecanedioic acid), DTPA‐H1P = 3,9‐di(carboxymethyl)‐6‐2‐hydroxy‐1‐phenylethyl‐3,6,9‐triazaundecanedioic acid, and DTPA‐H2P = 3,9‐di(carboxymethyl)‐6‐2‐hydroxy‐2‐phenylethyl‐3,6,9‐triazaundecanedioic acid were synthesized. Their protonation constants were determined by Potentiometric titration in 0.10 M Me₄NNO₃ and by NMR pH titration at 25.0 ± 0.1°C. The formations of lanthanide(III), copper(II), zinc(II) and calcium(II) complexes were investigated quantitatively by potentiometry. The stability constant for Gd(III) complex is larger than those for Ca(II), Zn(II) and Cu(II) complexes with these two ligands. The selectivity constants and modified selectivity constants of the DTPA‐H1P and DTPA‐H2P for Gd(III) over endogenously available metal ions were calculated. Comparing pM values at physiological pH 7.4 assesses effectiveness of these two ligands in binding divalent and trivalent metal ions in biological media. The observed water proton relaxivity values of [Gd(DTPA‐H1P)]^? and [Gd(DTPA‐H2P)]^? became constant with respect to pH changes over the range of 4‐10. ¹⁷O NMR shifts showed that the [Dy(DTPA‐H1P)]^? and [Dy(DTPA‐H2P)]^? complexes at pH 6.30 had 1.91 and 2.28 inner‐sphere water molecules, respectively. Water proton spin‐lattice relaxation rates of [Gd(DTPA‐H1P)]^? and [Gd(DTPA‐H2P)]^? complexes were also consistent with the inner‐sphere Gd(III) coordination.     

Toward optimized high-relaxivity MRI agents: thermodynamic selectivity of hydroxypyridonate/catecholate ligands

The thermodynamic selectivity for Gd(3+) relative to Ca(2+), Zn(2+), and Fe(3+) of two ligands of potential interest as magnetic resonance imaging (MRI) contrast agents has been determined by NMR spectroscopy and potentiometric and spectrophotometric titration. The two hexadentate ligands TREN-6-Me-3,2-HOPO (H(3)L2) and TREN-bisHOPO-TAM-EA (H(4)L3) incorporate 2,3-dihydroxypyridonate and 2,3-dihydroxyterephthalamide moieties. They were chosen to span a range of basicity while maintaining a structural motif similar to that of the parent ligand, TREN-1-Me-3,2-HOPO (H(3)L1), in order to investigate the effect of the ligand basicity on its selectivity. The 1:1 stability constants (beta(110)) at 25 degrees C and 0.1 M KCl are as follows. L2: Gd(3+), 20.3; Ca(2+), 7.4; Zn(2+), 11.9; Fe(3+), 27.9. L3: Gd(3+), 24.3; Ca(2+), 5.2; Zn(2+), 14.6; Fe(3+), 35.1. At physiological pH, the selectivity of the ligand for Gd(3+) over Ca(2+) increases with the basicity of the ligand and decreases for Gd(3+) over Fe(3+). These trends are consistent with the relative acidities of the various metal ions;- more basic ligands favor harder metals with a higher charge-to-radius ratio. The stabilities of the Zn(2+) complexes do not correlate with basicity and are thought to be more influenced by geometric factors. The selectivities of these ligands are superior to those of the octadentate poly(aminocarboxylate) ligands that are currently used as MRI contrast agents in diagnostic medicine.     

Toward optimized high-relaxivity MRI agents: the effect of ligand basicity on the thermodynamic stability of hexadentate hydroxypyridonate/catecholate gadolinium(III) complexes

The thermodynamic stabilities of the Gd(III) complexes of five hexadentate ligands, which incorporate the 2,3-dihydroxyterephthalamide and 2,3-hydroxypyridonate chelating moieties, have been determined by potentiometric and spectrophotometric titration. The ligands were chosen to span a range of basicities while maintaining a similar tripodal structural motif, facilitating a study of the effect of ligand basicity on the thermodynamic stability of the Gd(III) complexes. The relative stability of the five complexes is found to be highly pH dependent, with the most acidic ligands forming the most stable complexes at low pH and more basic ligands forming more stable complexes at high pH. The most stable Gd(III) complex at a physiological pH of 7.4 is formed with a ligand of intermediate basicity and is of stability comparable to that of Gd(III) complexes that feature eight-coordinate amino-carboxylate ligands and are currently used as magnetic resonance imaging contrast agents in diagnostic medicine. A single-crystal X-ray structure of the intermediate compound 3-hydroxy-6-methyl-2-oxo-1,2-dihydropyridine-4-carboxylic acid ethyl ester is described: This compound crystallizes in the triclinic space group P1 with a = 7.4801(3) A, b = 8.0671(3) A, c = 8.3457(4) A, alpha = 72.242(2) degrees, beta = 80.693(2) degrees, gamma = 69.943(3) degrees, V = 449.60(3) A(3), Z = 2, and R = 0.042.     

Induced circular dichroism by complexation of gadolinium(III) porphyrinates with chiral amino acids and dipeptides: effects of axial β-diketonate ligands on chirality sensing and recognition

Synthetic gadolinium(III)porphyrins with various achiral β-diketonates as axial ligands in benzene solutions extracted chiral -amino acids and dipeptides from aqueous phases to give intense induced CD peaks in the Soret region via 1:1 supercomplexation. Their CD spectral shapes were dependent on the stereochemistry at the -positions of amino acids and of the C-terminal components of dipeptides: a reverse S-shape for the -form and an S-shape for the -form. When chiral 3-acetylcamphorate was introduced as an axial ligand, Gd(III)porphyrins showed CD spectral changes by supercomplexation with chiral alanylalanine; (+)-acetylcamphorate ligating Gd(III)porphyrin offered larger CD signal with the - or -form than the corresponding (−)-type Gd(III)porphyrin did, while the former afforded smaller CD peaks by supercomplexation with the - or -form than the latter Gd(III)porphyrin.